Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APN1125 in schizophrenia
NCT02724917Phase 2Suspended
- Sponsor
- CoMentis, Inc.
- Start
- Apr 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of APN1125 in schizophrenia, sponsored by CoMentis, Inc.. Started Apr 2016; status: suspended.
02
Drugs
APN1125
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02724917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02724917.